BMS Just Bet $15 Billion on China's Hottest Drug Factory
Bristol Myers Squibb just signed a deal worth up to $15.2 billion with China's Hengrui Pharmaceuticals, covering 13 early-stage drug programs. It's one of the year's biggest cross-border pharma transactions, and it's happening despite U.S.-China tensions that should theoretically make deals like this impossible.
The Biggest Check of the Year Has a Chinese Address
Bristol Myers Squibb just wrote a check that would make most biotech CEOs faint. The pharma giant signed a deal with China's Hengrui Pharmaceuticals worth up to $15.2 billion, making it one of the largest cross-border pharma transactions of the year. And it comes at a time when Washington and Beijing can barely agree on the weather.
But before you picture BMS buying Hengrui outright, pump the brakes. This isn't an acquisition. It's a sprawling collaboration and licensing agreement, structured more like a long-term business marriage than a one-time purchase. Think of it as putting a ring on 13 drug programs, with the big payoff coming only if those programs actually work.
What's Actually in the Box
The deal covers 13 early-stage programs across oncology, hematology, and immunology. The structure breaks down into three buckets:
Four oncology and hematology assets from Hengrui's pipeline, headed to BMS.
Four immunology assets from BMS's own shelves, headed to Hengrui.
Five new programs the two companies will discover and develop together from scratch.
Neither company has publicly named the specific drug candidates involved, which adds a layer of mystery (and, let's be honest, frustration for analysts trying to model the deal).
Geographically, the rights split neatly. BMS gets exclusive worldwide rights to Hengrui's assets outside mainland China, Hong Kong, and Macau. Hengrui keeps those territories for itself and picks up rights to BMS's immunology assets within the same region. It's the classic "you take your side of the world, I'll take mine" playbook that's become standard in cross-border pharma licensing.
Follow the Money
That $15.2 billion headline number is eye-catching, but it's important to understand what it actually means. Most of that figure is contingent value: option payments, development milestones, regulatory milestones, and commercial milestones that only pay out if things go well.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The guaranteed near-term cash is much smaller. BMS will pay $600 million upfront, followed by a $175 million payment on the first anniversary and another $175 million contingent payment in 2028. That's up to $950 million in near-term payments, which is serious money but a fraction of the headline number.
Hengrui also gets tiered royalties on net sales outside its home territory, meaning the deal keeps paying if products eventually hit the market. The transaction still needs to clear Hart-Scott-Rodino antitrust review, with closing expected sometime in Q3 2026.
Why BMS Needs This Deal
Bristol Myers Squibb has a problem, and it rhymes with "patent cliff." The company is staring down loss of exclusivity on major revenue drivers like Eliquis and Opdivo. When your biggest earners are approaching their expiration dates, you need fresh pipeline assets the way a restaurant running out of ingredients needs a new supplier.
BMS has been on an acquisition tear to address this. In 2024 alone, the company bought Karuna Therapeutics (schizophrenia), RayzeBio (radiopharmaceuticals), and Mirati Therapeutics (lung cancer). In 2025, it partnered with BioNTech on a bispecific antibody and acquired Orbital Therapeutics to bolster its cell therapy portfolio.
The Hengrui deal fits the same pattern but takes a different approach. Instead of buying a whole company, BMS is essentially renting access to Hengrui's early-stage innovation engine. More than 60% of BMS's current development pipeline is externally sourced, according to the company, so this isn't a new strategy; it's just a much bigger bet on the same playbook.
Wall Street's Verdict: Interesting, but Prove It
Analysts greeted the deal with polite enthusiasm, not champagne. BMO reiterated a Market Perform rating with a $60 price target, noting that the collaboration adds potential revenue beyond the patent cliff but needs more work to fully close the gap. Bernstein kept its own Market Perform at $58, calling the deal a way to accelerate early development through the "trough years" of 2028 to 2030.
The consensus? The deal is strategically smart but not a valuation game-changer in the near term. Most of the assets are early stage, which means they're years away from generating revenue. Investors are treating the $15.2 billion as potential value, not guaranteed value. It's a bit like praising someone for planting an orchard; the trees look promising, but nobody's tasting fruit yet.
The Elephant in the Room: Geopolitics
Let's address what makes this deal genuinely fascinating: the geopolitical backdrop. U.S.-China relations are, to put it diplomatically, complicated. The BIOSECURE Act has raised concerns about Western pharma's ties to Chinese companies, and overseas venture capital flowing into China has dropped sharply.
But here's what's remarkable: licensing deals between Western pharma and Chinese biotechs haven't just survived the tension. They've exploded. In 2025, China-origin out-licensing hit roughly $137.7 billion in disclosed deal value across about 186 transactions. And 2026 is tracking even higher, with 38 deals by mid-February alone. The average deal size jumped 76% year over year.
The BIOSECURE Act, it turns out, is narrower than many feared. It primarily targets specific Chinese contract manufacturers (like WuXi AppTec), not IP licensing deals or clinical data transfers. Western companies can still license Chinese drug assets; they just need to watch the manufacturing supply chain carefully.
For BMS, the calculus is straightforward. Hengrui has over 100 proprietary candidates in clinical development and more than 400 clinical trials running. It has secured FDA Fast Track designation for four drugs and Orphan Drug Designation for six others. That kind of pipeline depth is hard to find anywhere, let alone at licensing economics rather than full acquisition prices.
The Bigger Picture
This deal is a signal flare for the entire industry. Despite tariffs, political posturing, and regulatory scrutiny, the science doesn't care about borders. Chinese biotechs have evolved from generics manufacturers into legitimate innovation engines, and Western pharma companies are increasingly willing to pay for access.
Hengrui itself has completed 13 overseas business development transactions since 2023, partnering with the likes of MSD, GSK, Merck KGaA, and now BMS. The company licensed its next-generation PARP1 inhibitor to Merck KGaA and struck a deal with GSK to develop up to 12 medicines across respiratory, immunology, and oncology.
For BMS specifically, the Hengrui collaboration is a bet that the best way to survive the patent cliff isn't just buying companies; it's building bridges to where the innovation is happening fastest. Whether those bridges hold up against the winds of geopolitics is the multibillion-dollar question nobody can answer yet.
Clinical & Regulatory4 min read
The Biotech Stock That Crashed, Then Pulled a Houdini
Capricor's Duchenne drug got crushed 9-3 at an FDA advisory committee, and its stock cratered to $4. Then the FDA agreed to review an amended filing, and everything changed overnight. The comeback story Wall Street didn't see coming.
